Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Sexually Transmitted Diseases (STDs)


Section Navigation
			
			CDC Home








Guidance on the Use of Expedited Partner Therapy in the Treatment of Gonorrhea						Print
																Related Pages
										Expedited Partner Therapy (EPT) is a partner treatment approach where sex partners of patients who test positive for certain sexually transmitted diseases are provided treatment without previous medical evaluation. Because of EPT’s effectiveness in reducing gonorrhea reinfection rates**1**, CDC has recommended its use since 2006 for the heterosexual partners of patients diagnosed with gonorrhea if it was unlikely the partners would seek timely evaluation and treatment.**2**
At present, the only CDC-recommended treatment of uncomplicated urogenital, anorectal, and pharyngeal gonorrhea is monotherapy with a single intramuscular dose of ceftriaxone 500 mg. If EPT via injection is not possible, CDC recommends 800mg cefixime orally in a single dose.**3** CDC continues to recommend EPT for heterosexual men and women with gonorrhea for whom health department partner-management strategies are impractical or unavailable and whose providers are concerned about partners’ access to prompt clinical evaluation and treatment. This document is intended to provide guidance to providers who choose to use EPT for gonorrhea, and to answer frequently asked questions.
**1. In light of CDC’s recent changes to its gonorrhea treatment recommendations, can EPT be used for gonorrhea?**
Under current guidelines every effort should be made to ensure that a patient’s sex partners are evaluated and treated with the recommended regimen (a single dose of ceftriaxone 500 mg IM). However, because that is not always possible, providers should still consider EPT for partners of patients diagnosed with gonorrhea who are unlikely to access timely evaluation and treatment. MSM with gonorrhea have a high risk for coexisting infections (especially undiagnosed HIV) among their partners, and they might have partners without HIV who could benefit from PrEP. Data are also limited regarding the effectiveness of EPT in reducing persistent or recurrent gonorrhea among MSM **(4,5)**; thus, shared clinical decision-making regarding EPT for MSM is recommended.**2. Since CDC no longer recommends exclusively oral treatment for gonorrhea, how does CDC recommend EPT be practiced for gonorrhea?**
In cases where gonorrhea expedited partner therapy (provision of prescriptions or medications for the patient to take to his or her sex partner without the health care provider first examining the partner) is permissible by state law and the partner is unable or unlikely to seek timely treatment, the partner may be treated with a single 800 mg dose of cefixime, if a chlamydia infection in the patient has been excluded. If a chlamydia test result has not been documented, the partner may be treated with a single dose of oral cefixime 800 mg plus oral doxycycline 100 mg 2 times/day for 7 days. If adherence with multiday dosing is a considerable concern, azithromycin 1 g can be considered but has lower treatment efficacy among persons with rectal chlamydia (see Chlamydial Infections). As has always been the case, medication or prescriptions provided as part of EPT should be accompanied by treatment instructions, appropriate warnings about taking medications (if the partner is pregnant or has an allergy to the medication), general gonorrhea health education and counseling, and a statement advising that partners seek personal medical evaluation, particularly women with symptoms of PID.****6****Golden MR, Whittington WL, Handsfield HH, Hughes JP, Stamm WE, Hogben M, Clark A, Malinski C, Helmers JR, Thomas KK, Holmes KK. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med. 2005 Feb 17;352(7):676-85.
Centers for Disease Control & Prevention (CDC). 2015 Sexually Transmitted Diseases Treatment Guidelines. Atlanta: U.S. Department of Health and Human Services; 2015. Accessed Aug. 19, 2015.
St. Cyr S, Barbee L, Workowski KA, et al. Update to CDC’s Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep 2020;69:1911–1916. DOI: http://dx.doi.org/10.15585/mmwr.mm6950a6.
Stekler J, Bachmann L, Brotman RM, et al. Concurrent sexually transmitted infections (STIs) in sex partners of patients with selected STIs: implications for patient-delivered partner therapy. Clin Infect Dis. 2005;40:787–93.
Schillinger J, Jamison K, Slutsker J, et al. STI and HIV infections among MSM reporting exposure to gonorrhea or chlamydia: implications for expedited partner therapy. Sex Transm Infect. 2019;95:A107.
Expedited Partner Therapy. August 9, 2012. Available at: https://www.cdc.gov/std/ept/default.htm. Accessed Aug. 6, 2013
							
					
							Last Reviewed:  November 3, 2023						Source: 	Division of STD Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeSexually Transmitted Diseases (STDs)
Diseases & Related Conditionsplus icon
Bacterial Vaginosis (BV)
Chlamydia
Gonorrhea
Hepatitis
Herpes
HIV/AIDS & STDs
Human Papillomavirus (HPV)
*Mycoplasma genitalium (Mgen)*
Pelvic Inflammatory Disease (PID)
STDs & Infertility
STDs during Pregnancyplus icon
Fact Sheet
Detailed Fact Sheet
Statistics
Treatment and Care
Archive
STD Risk and Oral Sex
Syphilis
Trichomoniasis
Other STDsplus icon
Archive
Life Stages and Populationsplus icon
Adolescents and Young Adultsplus icon
Adolescents and Technology
Adolescents and STDs Fact Sheet
Gay, Bisexual and Other MSMplus icon
Gay Men & STDs Fact Sheet
Preventionplus icon
Guidance During Disruption of STD Clinical Services
Just Diagnosed?
Which STD Tests Should I Get?
STD Lowdown Infographic
Program Management & Evaluation Toolsplus icon
Effective Interventions
Gap Assessment Toolkit
Internet Partner Services Toolkit
Outbreak Response Resourcesplus icon
Congenital Syphilis HAN Template
Disseminated Gonococcal Infection HAN Template
Gonorrhea with Reduced Susceptibility HAN Template
LGV HAN Template
Practical Use of Program Evaluation
Program Operations Guidelines
S.P.A.C.E. Monkey
STD Informatics and Surveillance
Projects & Initiativesplus icon
EHE: Scaling Up HIV Prevention Services in STD Specialty Clinics
Gonococcal Isolate Surveillance Project (GISP)
Disease Interventionplus icon
Disease Intervention Training Centers
National Disease Intervention Specialists (DIS) Recognition Day
Resources
National Network of Prevention Training Centers (NNPTC)
STD PCHDplus icon
CDC DIS Workforce Development Funding
Guidance
STD Health Equityplus icon
Community Approaches to Reducing STDs
Sexual Health Cultural Competence Resources
Archive
STD Surveillance Network (SSuN)
Archive
Statisticsplus icon
STI Surveillance 2022
Gonococcal Isolate Surveillance Project Profiles
Syphilis Supplement
STI Prevalence, Incidence, and Cost Estimatesplus icon
At A Glance
Social Media Materials
Indian Health Service Reports
Social Media & Moreplus icon
The State of STIs Infographicplus icon
Customizable
HTML version
SDSB Contacts
Archive
Tools & Materialsplus icon
Brochuresplus icon
The Facts Brochures
Fact Sheets
Infographics
Provider Pocket Guides
Social Media Resources
Videos and Podcastsplus icon
Let’s Talk About Sexual Health
Safe in the City
Webinars
Widgets
Archive
Trainingplus icon
STD Prevention Courses
SASSI – SAS Training
STD Clinical Slidesplus icon
STD Clinical Slides
STD Picture Cardsplus icon
STD Picture Cards
Treatment and Screeningplus icon
Availability of STI Testing & Treatment Products
Duty to Warn
Expedited Partner Therapyplus icon
Gonorrhea Guidance
Legal Status of EPT
Legal/Policy Toolkit
Laboratory Information
Prenatal Syphilis Screening Laws
STD QCSplus icon
STD QCS Webinar Questions
STI Treatment Guidelines, 2021
A Guide to Taking a Sexual History
Additional Resources
Archive
About the Division of STD Preventionplus icon
STI Funding at Workplus icon
STI Prevention Success Stories
Success Bulletins
Strategic Plan 2022-2026
Fundingplus icon
Funding Archive
Archive For Healthcare Providers For Public Health Professionals Follow STD STD on Twitter
STD on Facebook


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue